본문영역 바로가기
ABL Bio - medicine for A Better Life
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL602
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
KOR
ENG
모바일 메뉴 보기
Investors & Media
News
Home
Investors & Media
News
[머니S] 글로벌도 군침… 바이오도 플랫폼 시대 왔다
2022-10-07
ablbio
https://moneys.mt.co.kr/news/mwView.php?no=2022100616263076734
list
PREV
ABL Bio receives near-term milestone for ABL301
NEXT
ABL Bio enters the phase 1 expansion part of global clinical trials by applying for phase 1 of ABL503 in Korea
ABL Bio
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL602
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
메뉴닫기